Article info

Download PDFPDF

Therapeutic innovation in adult-onset Still’s disease (and other rare inflammatory disorders): how to secure evidence-based medicine?
Free

Authors

  • Philippe Guilpain Medical School, Montpellier University, Montpellier, France Department of Internal Medicine – Multi-Organic Diseases, Local Referral Center for Autoimmune Diseases, University of Montpellier, Saint-Eloi Hospital, Montpellier, France Institute for Regenerative Medicine and Biotherapy (IRMB), Inserm, U1183, Saint-Eloi Hospital, Montpellier, France PubMed articlesGoogle scholar articles
  • Alain Le Quellec Medical School, Montpellier University, Montpellier, France Department of Internal Medicine – Multi-Organic Diseases, Local Referral Center for Autoimmune Diseases, University of Montpellier, Saint-Eloi Hospital, Montpellier, France PubMed articlesGoogle scholar articles
  • Alexandre Thibault Jacques Maria Medical School, Montpellier University, Montpellier, France Department of Internal Medicine – Multi-Organic Diseases, Local Referral Center for Autoimmune Diseases, University of Montpellier, Saint-Eloi Hospital, Montpellier, France Institute for Regenerative Medicine and Biotherapy (IRMB), Inserm, U1183, Saint-Eloi Hospital, Montpellier, France PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Philippe Guilpain, Department of internal medicine, Multi-Organic Diseases, St Eloi Hospital, CHRU de Montpellier, Montpellier, F-34295, France; p-guilpain{at}chu-montpellier.fr
View Full Text

Citation

Guilpain P, Le Quellec A, Maria ATJ
Therapeutic innovation in adult-onset Still’s disease (and other rare inflammatory disorders): how to secure evidence-based medicine?

Publication history

  • Received March 29, 2018
  • Revised May 14, 2018
  • Accepted May 15, 2018
  • First published June 2, 2018.
Online issue publication 
November 16, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.